Effect of Rivaroxaban on coagulation parameters in patients undergoing elective orthopaedic surgery

F. Wenger, H. Mani, C. Hesse, E. Lindhoff-Last, A. Meurer & I. Marzi
Objective: Rivaroxaban (Xarelto®) represents the first oral direct factor Xa inhibitor and is increasingly used for prevention of thrombosis after hip or knee replacement surgery after approval in 2008 in the European Union. Yet iIts influence on laboratory coagulation parameters is unclear and[for full text, please go to the a.m. URL]